Search Result

Basic Information

Classification Information

Regulatory Mechanism		Biological Function		Clinical Application
TF		Immune		Survival
Enhancer		Apoptosis		Drug
Variant		Cell Growth		Circulating
MiRNA		EMT		Metastasis
Methylation		Coding Ability		Recurrence

Cancer&Entry Information

Cancer Name	osteosarcoma
ICD-0-3	NA
Methods	qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP
Sample	OS tissues, OS cell lines (MG-63, 143B, MHM and SJSA1)
Expression Pattern	up-regulated
Function Description	XIST expression was significantly upregulated in OS tissues and cell lines and negatively correlated with clinical prognosis.XIST knockdown inhibited cancer cell proliferation and invasion in vitro, inhibited the EMT of OS cells in vitro, and suppressed subcutaneous tumor growth in vivo. Further analysis demonstrated that XIST regulated YAP expression by functioning as a competing endogenous RNA that sponged miR-195-5p in OS cells. XIST directly interacted with miR-195-5p and decreased the binding of miR-195-5p to the YAP 3'UTR, which suppressed the degradation of YAP mRNA by miR-195-5p.
Pubmed ID	29384226
Year	2018
Title	The expression of LncRNA RP11-87C12.5 is high in newly diagnosed ALL group and low in complete remission ALL group. In B-ALL, the expression of IncRNA RP11-87C12.5 significantly enhances in cCD79a low expression group. In newly diagnosed ALL group, compared with low expression group, lncRNA RP11-87C12.5 high expression group have higer remission rate and relapse rate, but the difference was not statistically significant.Long non-coding RNA XIST promotes osteosarcoma progression by targeting YAP via miR-195-5p.

External Links